Study in Japan of the Safety And Antiviral Activity in Adults With Chronic Hepatitis B Current Lamivudine Therapy

Phase 2

Completed

Conditions: Chronic Hepatitis B

Interventions: Drug: Entecavir

Registration Number: NCT01037166

Lead Sponsor: Bristol-Myers Squibb

Brief Summary: The objectives are to demonstrate that entecavir has antiviral activity undetectable HBV DNA measured, the Roche AmplicorTM PCR at Week 48, and to assess the safety and the pharmacokinetic of entecavir in Japanese patients with hepatitis B who have an incomplete response to current lamivudine therapy

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 84

Inclusion Criteria

Documentation of chronic hepatitis B infection by ALL of the following:
1. Positive for HBsAg OR, negative for IgM core antibody and confirmation of chronic hepatitis B on liver biopsy
2. Patient who have received lamivudine therapy for 24 weeks or more, or patient who have documented YMDD mutation or other lamivudine-resistant mutation while on lamivudine
3. Documented HBV Viremia ≥ 10*5: copies/mL
ALT in the range of 1.3 to 10 x ULN
Subjects must have well-compensated liver disease a) value

Exclusion Criteria

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Entecavir (0.5 mg)	Entecavir	-
Entecavir (1mg)	Entecavir	-

Primary Outcome Measures

Name	Time	Method
To assess the safety (the incidence of clinical adverse events and discontinuations due to adverse events)	Week 52 (end of dosing) plus 5 days
To assess the proportion of subjects with reduction in HBV DNA by ≥ 2 log10 or to undetectable level (< 400 copies/mL)	at Week 48

Secondary Outcome Measures

Name	Time	Method
Mean change from baseline in the log10 HBV DNA measured by PCR assay for each entecavir dose (0.5 and 1 mg) at Week 48	Baseline, Week 48
Proportion of subjects who achieve undetectable HBV DNA (<400 copies/mL) by PCR assay at Week 48	Week 48
Proportion of subjects HBeAg-positive at baseline who have loss of HBeAg from serum at Week 48	Week 48
Proportion of subjects HBeAg-positive at baseline who achieve seroconversion (loss of HBeAg and appearance of HBeAb) at Week 48	Week 48
Proportion of subjects with abnormal ALT at baseline who achieve normalization of serum ALT (<1.25 x ULN) at Week 48	Week 48
Proportion of subjects HBeAg-positive at baseline who have complete response (undetectable HBV DNA levels by PCR assay, negative for HBeAg and normal serum ALT) at Week 48	Week 48
Proportion of subjects HBeAg-negative at baseline who have undetectable HBV DNA levels by PCR assay, remain negative for HBeAg and normal serum ALT at Week 48	Week 48
Proportion of subjects w/ histological improvement in liver (improvement in necroinflammatory score (≥2 points decrease, Knodell HAI3 score) & no worsening of fibrosis (≥1 point increase, Knodell fibrosis score) at Wk 48 liver biopsy compared to baseline	Baseline, Week 48
Changes in liver histology as assessed by the New Inuyama Classification for histological assessment of chronic hepatitis	Week 52
Relationship between HBV isolates (genotypes A,B,C, etc.) at baseline and antiviral activity	Week 48, or at end of dosing (up to Week 52)
Incidence of resistance mutations of HBV isolates in subjects who have a rise in HBV DNA (by ≥1 log above the nadir for that subject) while on study drug.	Week 48, or at end of dosing (up to Week 52)
Mutation of HBV DNA polymerase at Week 48 from baseline	Baseline, Week 48
Plasma concentrations of entecavir at selected time points during the treatment period	pre-dosing, Week 2 or 4, Week 12, Week 24 and Week 36
Population pharmacokinetic assessment of entecavir developed from concentration-time data obtained from healthy subjects	pre-dosing, Week 2 or 4, Week 12, Week 24 and Week 36